The Five Major Themes Of The Pharmaceutical Industry In The United States
The brilliant listing of 46 new drugs in the United States in 2017 is over and the promising 2018 is coming. With the emergence of new technologies, the near-limit of payment capacity and the unmet medical needs, the development of the pharmaceutical industry in the United States will still be ups and downs and exciting in 2018. Here are some of the main themes of the U.S. pharmaceutical industry in 2018.
1. The number of new drugs continue to rise, limiting the price of drug
In 2017, the U.S. Food and Drug Administration (FDA) approved a total of 46 new drugs to be listed on the market with a 20-year update record. The reason, one of the most central factor is the development of new drugs more accurate. The development of precision medicine has been more developed, increasing the success rate of listing new drugs and also making the disease more subdivided and increasing the number of drug indications. Together, the two are "engines" for new drug production. Coupled with the "friendly attitude" of the FDA, the number of new drugs will remain high in 2018 and an estimated 35 to 40 new molecular drugs will be listed.
In addition, the United States has been the voice of the drug control has been high, but the United States because of cultural support for innovation, so the introduction of drug prices less likely to control. Drug expenditures will be controlled primarily through faster drug approval, the use of generic drugs and the encouragement of competition from similar products.
2. Immunotherapy from the "magic medicine" to the return of good medicine
The industry's expectation of immunotherapy is becoming more rational. 2018 there will be more small molecule IO drug phase III clinical results disclosed. Combination therapy, which is highly anticipated by the industry, has not yet passed the rigorous clinical trials. The much anticipated IDO inhibitor may be the most disappointing drug of 2018. Therefore, targeted therapies may once again become the focus of cancer drug development.
3. High-tech continue to expand the treatment space
RNA drugs are mainstreamed in 2016, 2017 is the first year of CAR-T and gene therapy, and it is clear that these technologies will continue to grow in 2018. With the arrival of mRNA drugs in the clinic, RNA drugs are on the way to market, and RNA drugs are expected to further compete with traditional drugs. SMA and hemophilia gene therapy are also expected to complete late-stage clinical trials. Another major breakthrough in technology transformation in 2018 may be gene editing technology. Today, Sangamo's ZFN Editorial Technical Drug is the first to enter human trials, while CRISPR Therapeutic's Thalassemia drugs have been approved for clinical trials. In 2017, a number of technologies such as pre-antibody, DEL, and antibody subcutaneous injection technology are supported by major pharmaceutical companies. This trend is expected to continue this year.
Although drug prices will not be limited for the time being, the space for increasing drug prices will be severely restricted and the competition for finding new products will be even more fierce. As the transformation of basic research is increasingly valued by scientists, venture capital in biotechnology remains strong, so early projects are well supplied. The development of pharmaceutical companies speed and experience is the new project to complete proof of concept high-speed, to the market a shortcut. Therefore, the cooperation between big pharmaceutical companies and small biotech companies will continue to deepen. The tax reform in the United States has led pharmaceutical companies to return huge amounts of cash, greatly boosting their spending power. It is also likely that the acquisition of major pharmaceutical companies such as Squibb, which possess "overweight pounds" drugs, will also surge.
4. Premium assets are more tight
5. Small molecule drugs need deep innovation
Traditional small molecule drugs face a variety of new technologies to squeeze, want to continue based on the need for more in-depth innovation. DNA coding technology significantly expands the space for small molecule chemistry. PROTAC makes therapies theoretically effective at catalysis, but these techniques are similar to football's inverted hooks and, although they may play an extraordinary role in exceptional circumstances, can not subvert the entire field . Small molecule drugs to continue to survive Need for small intracellular targets for more in-depth study, in selective, cell, animal evaluation of the efficacy of high-tech to be introduced.